Home Cart Sign in  
Chemical Structure| 905306-69-6 Chemical Structure| 905306-69-6

Structure of 905306-69-6

Chemical Structure| 905306-69-6

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of [ 905306-69-6 ]

CAS No. :905306-69-6
Formula : C7H10N2O
M.W : 138.17
SMILES Code : NCC1=NC=C(OC)C=C1
MDL No. :MFCD10697534
InChI Key :AKYKNKLVGMYOIL-UHFFFAOYSA-N
Pubchem ID :17854247

Safety of [ 905306-69-6 ]

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Computational Chemistry of [ 905306-69-6 ] Show Less

Physicochemical Properties

Num. heavy atoms 10
Num. arom. heavy atoms 6
Fraction Csp3 0.29
Num. rotatable bonds 2
Num. H-bond acceptors 3.0
Num. H-bond donors 1.0
Molar Refractivity 38.4
TPSA ?

Topological Polar Surface Area: Calculated from
Ertl P. et al. 2000 J. Med. Chem.

48.14 Ų

Lipophilicity

Log Po/w (iLOGP)?

iLOGP: in-house physics-based method implemented from
Daina A et al. 2014 J. Chem. Inf. Model.

1.61
Log Po/w (XLOGP3)?

XLOGP3: Atomistic and knowledge-based method calculated by
XLOGP program, version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry

-0.28
Log Po/w (WLOGP)?

WLOGP: Atomistic method implemented from
Wildman SA and Crippen GM. 1999 J. Chem. Inf. Model.

0.4
Log Po/w (MLOGP)?

MLOGP: Topological method implemented from
Moriguchi I. et al. 1992 Chem. Pharm. Bull.
Moriguchi I. et al. 1994 Chem. Pharm. Bull.
Lipinski PA. et al. 2001 Adv. Drug. Deliv. Rev.

-0.39
Log Po/w (SILICOS-IT)?

SILICOS-IT: Hybrid fragmental/topological method calculated by
FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com

0.93
Consensus Log Po/w?

Consensus Log Po/w: Average of all five predictions

0.45

Water Solubility

Log S (ESOL):?

ESOL: Topological method implemented from
Delaney JS. 2004 J. Chem. Inf. Model.

-0.83
Solubility 20.3 mg/ml ; 0.147 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Very soluble
Log S (Ali)?

Ali: Topological method implemented from
Ali J. et al. 2012 J. Chem. Inf. Model.

-0.27
Solubility 73.9 mg/ml ; 0.535 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Very soluble
Log S (SILICOS-IT)?

SILICOS-IT: Fragmental method calculated by
FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com

-2.17
Solubility 0.936 mg/ml ; 0.00678 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Soluble

Pharmacokinetics

GI absorption?

Gatrointestinal absorption: according to the white of the BOILED-Egg

High
BBB permeant?

BBB permeation: according to the yolk of the BOILED-Egg

No
P-gp substrate?

P-glycoprotein substrate: SVM model built on 1033 molecules (training set)
and tested on 415 molecules (test set)
10-fold CV: ACC=0.72 / AUC=0.77
External: ACC=0.88 / AUC=0.94

No
CYP1A2 inhibitor?

Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set)
and tested on 3000 molecules (test set)
10-fold CV: ACC=0.83 / AUC=0.90
External: ACC=0.84 / AUC=0.91

No
CYP2C19 inhibitor?

Cytochrome P450 2C19 inhibitor: SVM model built on 9272 molecules (training set)
and tested on 3000 molecules (test set)
10-fold CV: ACC=0.80 / AUC=0.86
External: ACC=0.80 / AUC=0.87

No
CYP2C9 inhibitor?

Cytochrome P450 2C9 inhibitor: SVM model built on 5940 molecules (training set)
and tested on 2075 molecules (test set)
10-fold CV: ACC=0.78 / AUC=0.85
External: ACC=0.71 / AUC=0.81

No
CYP2D6 inhibitor?

Cytochrome P450 2D6 inhibitor: SVM model built on 3664 molecules (training set)
and tested on 1068 molecules (test set)
10-fold CV: ACC=0.79 / AUC=0.85
External: ACC=0.81 / AUC=0.87

No
CYP3A4 inhibitor?

Cytochrome P450 3A4 inhibitor: SVM model built on 7518 molecules (training set)
and tested on 2579 molecules (test set)
10-fold CV: ACC=0.77 / AUC=0.85
External: ACC=0.78 / AUC=0.86

No
Log Kp (skin permeation)?

Skin permeation: QSPR model implemented from
Potts RO and Guy RH. 1992 Pharm. Res.

-7.34 cm/s

Druglikeness

Lipinski?

Lipinski (Pfizer) filter: implemented from
Lipinski CA. et al. 2001 Adv. Drug Deliv. Rev.
MW ≤ 500
MLOGP ≤ 4.15
N or O ≤ 10
NH or OH ≤ 5

0.0
Ghose?

Ghose filter: implemented from
Ghose AK. et al. 1999 J. Comb. Chem.
160 ≤ MW ≤ 480
-0.4 ≤ WLOGP ≤ 5.6
40 ≤ MR ≤ 130
20 ≤ atoms ≤ 70

None
Veber?

Veber (GSK) filter: implemented from
Veber DF. et al. 2002 J. Med. Chem.
Rotatable bonds ≤ 10
TPSA ≤ 140

0.0
Egan?

Egan (Pharmacia) filter: implemented from
Egan WJ. et al. 2000 J. Med. Chem.
WLOGP ≤ 5.88
TPSA ≤ 131.6

0.0
Muegge?

Muegge (Bayer) filter: implemented from
Muegge I. et al. 2001 J. Med. Chem.
200 ≤ MW ≤ 600
-2 ≤ XLOGP ≤ 5
TPSA ≤ 150
Num. rings ≤ 7
Num. carbon > 4
Num. heteroatoms > 1
Num. rotatable bonds ≤ 15
H-bond acc. ≤ 10
H-bond don. ≤ 5

1.0
Bioavailability Score?

Abbott Bioavailability Score: Probability of F > 10% in rat
implemented from
Martin YC. 2005 J. Med. Chem.

0.55

Medicinal Chemistry

PAINS?

Pan Assay Interference Structures: implemented from
Baell JB. & Holloway GA. 2010 J. Med. Chem.

0.0 alert
Brenk?

Structural Alert: implemented from
Brenk R. et al. 2008 ChemMedChem

0.0 alert: heavy_metal
Leadlikeness?

Leadlikeness: implemented from
Teague SJ. 1999 Angew. Chem. Int. Ed.
250 ≤ MW ≤ 350
XLOGP ≤ 3.5
Num. rotatable bonds ≤ 7

No; 1 violation:MW<1.0
Synthetic accessibility?

Synthetic accessibility score: from 1 (very easy) to 10 (very difficult)
based on 1024 fragmental contributions (FP2) modulated by size and complexity penaties,
trained on 12'782'590 molecules and tested on 40 external molecules (r2 = 0.94)

1.62

Application In Synthesis of [ 905306-69-6 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Downstream synthetic route of [ 905306-69-6 ]

[ 905306-69-6 ] Synthesis Path-Downstream   1~9

  • 1
  • [ 612095-46-2 ]
  • [ 905306-69-6 ]
  • [ 905306-63-0 ]
  • 2
  • [ 612095-43-9 ]
  • [ 905306-69-6 ]
  • [ 905306-62-9 ]
  • 5
  • [ 905306-69-6 ]
  • [ 126926-31-6 ]
  • C20H21N3O4 [ No CAS ]
  • 6
  • [ 905306-69-6 ]
  • [ 126926-31-6 ]
  • C20H19N3O4 [ No CAS ]
  • 7
  • [ 905306-69-6 ]
  • 2-chloro-3-methyl-7-(propan-2-yl)imidazo[5,1-f][1,2,4]triazin-4(3H)-one [ No CAS ]
  • 2-[(5-methoxypyridin-2-yl)methyl]amino}-3-methyl-7-(propan-2-yl)imidazo[5,1-f][1,2,4]triazin-4(3H)-one [ No CAS ]
YieldReaction ConditionsOperation in experiment
30% With N-ethyl-N,N-diisopropylamine; In N,N-dimethyl-formamide; at 50℃; for 10h; To a solution of <strong>[905306-69-6]1-<strong>[905306-69-6](5-methoxypyridin-2-yl)methanamine</strong></strong> (138 mg, 1 mmol) and 2-chloro-3-methyl-7-(propan-2-yl)imidazo[5,1-f][1,2,4]triazin-4(3H)-one (90 mg, 0.4 mmol) in DMF (1.5 mL) was added DIEA (104 mg, 0.8 mmol). The reaction mixture was stirred at 50C for 10 h and purified by preparative HPLC (MeCN and H2O with 0.01% NH3.H2O as mobile phase) to give the titled compound (40 mg, yield 30 %).LC-MS (m/z) = 329 [M + H]+.1H-NMR (400 MHz, DMSO-d6): delta 1.40 (d, J = 7.2 Hz, 6H), 3.46-3.52 (m, 1H), 3.53 (s, 3H), 3.89 (s, 3H), 4.55 (d, J = 4.0 Hz, 2H), 6.07 (s, 1H), 7.27-7.31 (m, 2H), 7.75 (s, 1H), 8.26 (d, J = 2.4 Hz, 1H).
  • 8
  • [ 905306-69-6 ]
  • [ 407-25-0 ]
  • 6-methoxy-3-(trifluoromethyl)imidazo[1,5-a]pyridine [ No CAS ]
  • 9
  • [ 905306-69-6 ]
  • (R)-2-(5-amino-2-(furan-2-yl)-7H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-7-yl)-2-phenylpropanoic acid [ No CAS ]
  • (R)-2-(5-amino-2-(furan-2-yl)-7H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-7-yl)-N-((5-methoxypyridin-2-yl)methyl)-2-phenylpropanamide [ No CAS ]
YieldReaction ConditionsOperation in experiment
69% To a mixture of (R) -2- (5-amino-2- (furan-2-yl) -7H-pyrazolo [4, 3-e] [1, 2, 4] triazolo [1, 5-c] pyrimidin-7-yl) -2-phenylpropanoic acid (50 mg, 0.13 mmol) , and DIPEA (70 mg, 0.54 mmol) in THF (1 mL) was added HATU (54 mg, 0.14 mmol) at rt and the mixture was stirred at rt for 10 min. A solution of (5-methoxypyridin-2-yl) methanamine (20 mg, 0.14 mmol) was added, and the mixture was stirred at rt for 16 hrs. The mixture was diluted with 5 mL of EtOAc, washed with brine (3 mL x 3) , dried over Na 2SO 4, and concentrated. The resulted residue was purified by prep-TLC (EtOAc, 100%) and the resulted solid was lyophilized to give the title product (45 mg, yield: 69%) . 1H NMR (400 MHz, DMSO-d6) delta 8.25 (s, 1H) , 8.17 -8.07 (m, 2H) , 8.02 (s, 2H) , 7.97 -7.92 (m, 1H) , 7.38 -7.26 (m, 5H) , 7.26 -7.19 (m, 3H) , 6.74 (dd, J = 3.2, 1.6 Hz, 1H) , 4.46 -4.26 (m, 2H) , 3.78 (s, 3H) , 2.38 (s, 3H) . MS: M/e 510 (M+1) +.
 

Historical Records

Technical Information

Categories

Related Functional Groups of
[ 905306-69-6 ]

Ethers

Chemical Structure| 194658-14-5

A100929 [194658-14-5]

(4-Methoxypyridin-2-yl)methanamine

Similarity: 0.85

Chemical Structure| 1624262-52-7

A131147 [1624262-52-7]

2-(5-Methoxypyridin-2-yl)ethanamine hydrochloride

Similarity: 0.84

Chemical Structure| 1344046-06-5

A142400 [1344046-06-5]

(4-Methoxypyridin-2-yl)methanamine dihydrochloride

Similarity: 0.84

Chemical Structure| 1179359-60-4

A144328 [1179359-60-4]

5-Methoxypicolinimidamide hydrochloride

Similarity: 0.84

Chemical Structure| 22187-96-8

A415348 [22187-96-8]

5-Methoxypicolinaldehyde

Similarity: 0.82

Amines

Chemical Structure| 194658-14-5

A100929 [194658-14-5]

(4-Methoxypyridin-2-yl)methanamine

Similarity: 0.85

Chemical Structure| 1624262-52-7

A131147 [1624262-52-7]

2-(5-Methoxypyridin-2-yl)ethanamine hydrochloride

Similarity: 0.84

Chemical Structure| 1344046-06-5

A142400 [1344046-06-5]

(4-Methoxypyridin-2-yl)methanamine dihydrochloride

Similarity: 0.84

Chemical Structure| 1179359-60-4

A144328 [1179359-60-4]

5-Methoxypicolinimidamide hydrochloride

Similarity: 0.84

Chemical Structure| 327056-65-5

A122595 [327056-65-5]

N-Hydroxy-5-methoxypicolinimidamide

Similarity: 0.78

Related Parent Nucleus of
[ 905306-69-6 ]

Pyridines

Chemical Structure| 194658-14-5

A100929 [194658-14-5]

(4-Methoxypyridin-2-yl)methanamine

Similarity: 0.85

Chemical Structure| 1624262-52-7

A131147 [1624262-52-7]

2-(5-Methoxypyridin-2-yl)ethanamine hydrochloride

Similarity: 0.84

Chemical Structure| 1344046-06-5

A142400 [1344046-06-5]

(4-Methoxypyridin-2-yl)methanamine dihydrochloride

Similarity: 0.84

Chemical Structure| 1179359-60-4

A144328 [1179359-60-4]

5-Methoxypicolinimidamide hydrochloride

Similarity: 0.84

Chemical Structure| 22187-96-8

A415348 [22187-96-8]

5-Methoxypicolinaldehyde

Similarity: 0.82